Canadian Journal of Kidney Health and Disease
First Published May 1, 2020
Judith G. Marin, Laura Beresford, Clifford Lo, Alexander Pai, Gabriela Espino-Hernandez, and Monica Beaulieu
Patients treated with maintenance dialysis are at high risk of polypharmacy given their many comorbidities as well as complications from their disease state and treatment. The prescribing patterns and burden of polypharmacy in patients treated with maintenance dialysis, and specifically the difference between hemodialysis (HD) and peritoneal dialysis (PD) prescribing, are not well characterized.